Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
New Biogen CEO tips subcutaneous lecanemab to help expansion into pre-symptomatic Alzheimer’s
Fierce Pharma
Fri, 01/13/23 - 10:59 am
Biogen
Chris Viehbacher
lecanemab
Alzheimer's disease
Pharma CEOs
Alzheimer’s disease trials: How does Lilly’s donanemab compare to lecanemab?
Clinical Trials Arena
Fri, 01/13/23 - 10:49 am
clinical trials
Alzheimer's disease
Eisai
Biogen
Eli Lilly
Leqembi
lecanemab
donanemab
After FDA nod, Eisai and Biogen file lecanemab in EU
Pharmaphorum
Wed, 01/11/23 - 11:04 pm
Eisai
Biogen
lecanemab
Europe
Alzheimer's disease
Lilly, Biogen and more gear up for blockbuster launches in 2023: report
Fierce Pharma
Wed, 01/11/23 - 11:00 pm
Clarivate
drug launches
Eli Lilly
Biogen
GSK
Bristol Myers Squibb
Biogen, scrapping for SMA market share, bets $10M on implant to improve delivery of Spinraza
Fierce Pharma
Tue, 01/10/23 - 10:55 am
Biogen
Alcyone Therapeutics
SMA
Spinraza
devices
Medtech
Eisai learns from Biogen’s Aduhelm disaster
EP Vantage
Mon, 01/9/23 - 10:35 am
Eisai
Biogen
Leqembi
Aduhelm
Alzheimer's disease
drug pricing
Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy
BioPharma Dive
Sun, 01/8/23 - 10:04 pm
Eisai
Biogen
drug pricing
Leqembi
Alzheimer's disease
lecanemab
FDA approves Alzheimer’s drug from Eisai, Biogen in closely watched decision
BioPharma Dive
Fri, 01/6/23 - 03:40 pm
Eisai
Biogen
lecanemab
Leqembi
Alzheimer's disease
FDA
Biogen and Alcyone Therapeutics partner up on novel device for neurological ASO therapies
Biopharma Reporter
Thu, 01/5/23 - 04:56 pm
devices
Medtech
Biogen
Alcyone Therapeutics
ThecaFlex DRx
ASO therapies
Biogen splits R&D executive role, promoting interim head Singhal
BioPharma Dive
Thu, 01/5/23 - 04:47 pm
Biogen
R&D
Biogen, FDA's inappropriate Aduhelm coordination detailed in blistering congressional report
Fierce Pharma
Fri, 12/30/22 - 10:50 am
Biogen
Aduhelm
Alzheimer's disease
FDA
US Congress
Eisai and Biogen’s latest Alzheimer’s drug needs to be cheaper than the last one, analysts say
Stat
Thu, 12/22/22 - 11:10 am
Biogen
Eisai
Alzheimer's disease
drug pricing
ICER
lecanemab
3rd patient death potentially tied to Eisai's Alzheimer's drug reported
Fierce Biotech
Thu, 12/22/22 - 11:05 am
Biogen
Eisai
Alzheimer's disease
clinical trials
patient deaths
lecanemab
Ahead of lecanemab decision, Alzheimer's groups petition CMS to reverse coverage policy
Endpoints
Wed, 12/21/22 - 11:31 am
Biogen
FDA
Alzheimer's disease
CMS
clinical trials
Roche takes over development of Biogen-partnered lymphoma drug
BioPharma Dive
Tue, 12/20/22 - 11:11 am
Roche
Biogen
lymphoma
glofitamab
Biogen's ALS Drug Tofersen Filing Accepted in Europe
Zacks.com
Tue, 12/6/22 - 10:48 am
Biogen
ALS
EMA
Europe
tofersen
Lilly’s Donanemab Shines vs. Aduhelm in First Active Comparator Study
BioSpace
Thu, 12/1/22 - 07:10 pm
Eli Lilly
donanemab
clinical trials
Aduhelm
Biogen
Alzheimer's disease
CTAD 2022 – lecanemab data hold up, with a big but
EP Vantage
Thu, 12/1/22 - 07:01 pm
Biogen
Eisai
Alzheimer's disease
CTAD
lecanemab
clinical trials
Go or no go? Mirati heads to the FDA
EP Vantage
Wed, 11/30/22 - 10:34 am
FDA
Mirati Therapeutics
Gilead Sciences
Coherus Biosciences
Roche
Biogen
TG Therapeutics
Ipsen
Novartis
BeiGene
Cytokinetics
What to make of Eisai and Biogen’s latest Alzheimer’s drug data
BioPharma Dive
Tue, 11/29/22 - 10:58 pm
Biogen
Eisai
Alzheimer's disease
lecanemab
Pages
« first
‹ previous
…
3
4
5
6
7
8
9
10
11
…
next ›
last »